SecBot SecBot

DRMA

Dermata Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001853816 Biotech & Drug Discovery
$0.7550 +0.04 (+5.15%)
Oct 27 4:00 PM ET · prev $0.7180
Market cap
$3.9M
Nano cap
Median target
$4.00
+430% · range $4.00–4.00
Next earnings
Nov 12
in 16 days · EPS est. −$0.55
1 year
−79.9%
from $3.76 · Oct 28
30 days
−32.6%
from $1.12
52-week range
$0.6630–3.76
−80% from high · low Oct 14
Avg volume 20D
8.77M
Oct 15 spike 170.52M
Short interest
77.3K
≈1.6% of shares · −8.5%
Days to cover
1.0
at average volume
Insider net
+$1.3K
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 2 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH Dermata Therapeutics' S-3 shelf registration (File No. 333-299391) was declared effective on October 20…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $1.3K at an average $1.27. 1 insider sold $13.09. Price is 41% below their cost.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 2 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.610 → −$0.550 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −8.5% to 77.3K shares. 1.0 days to cover, ≈1.6% of shares.

  • TrendDOWNTREND

    34% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM20,203$26.1K
UBS Group AGTRIM16,796$21.7K
UBS Group AGDOUBLED35,608$43.1K
BANK OF AMERICA CORP /DE/DOUBLED3,457$8.0K
UBS Group AGNEAR_EXIT1,237$2.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Aug 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +430%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Aug 21, 2025Maxim Group
MAINTAIN
MAINTAINBuy
May 21, 2025Maxim Group
MAINTAIN
MAINTAINBuy
Aug 21, 2024Maxim Group
MAINTAIN
MAINTAINBuy
Mar 23, 2023Maxim Group
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$1.3K
bought · 1 insider
$13.09
sold · 1 insider
−40.6%
vs their $1.27 cost
DateInsiderTypeValue
Aug 16, 2026
PROEHL GERALD T
PRESIDENT, CHAIRMAN, CEO
AWARD170,068 sh
Aug 16, 2026
PROEHL GERALD T
PRESIDENT, CHAIRMAN, CEO
AWARD170,068 sh
Aug 16, 2026
PROEHL GERALD T
PRESIDENT, CHAIRMAN, CEO
AWARD1,360,544 sh
Aug 16, 2026
PROEHL GERALD T
PRESIDENT, CHAIRMAN, CEO
AWARD1,360,544 sh
Aug 16, 2026
PROEHL GERALD T
PRESIDENT, CHAIRMAN, CEO
AWARD1,360,544 sh
Aug 16, 2026
PROEHL GERALD T
PRESIDENT, CHAIRMAN, CEO
AWARD170,068 sh
Aug 16, 2026
Van Hoose Kyri K.
SVP, CFO
AWARD102,040 sh
Aug 16, 2026
Van Hoose Kyri K.
SVP, CFO
AWARD102,040 sh

Earnings setup

Estimates
Nov 12
reports in 16 days
−$0.55
EPS estimate, this quarter
+10%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.55-$0.55–-$0.55+12.7%$25.0K
Next Q-$0.46-$0.46–-$0.46+17.9%$75.0K
Current FY-$2.17-$2.17–-$2.17+1.8%$100.0K
Next FY-$1.43-$1.43–-$1.43+5.9%$750.0K

Short side

FINRA· Oct 15, 2026
77,279
shares short
-8.5%
vs prior settlement
1.0
days to cover
≈1.6%
of shares outstanding
Trading halts
Oct 15, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Dermata Therapeutics' S-3 shelf registration (File No. 333-299391) was declared effective on October 20, 2026…
EFFECT — Impact 6/10
Oct 15, 2026 Trading halt
Halt Resumed: DRMA — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-15T14:26:49.000Z | Resumed 2026-10-15T14:31:49.000Z
Oct 9, 2026 SEC
Dermata Therapeutics filed an S-3 registration statement to register up to 6,919,560 shares of common stock for resale…
S-3 — Impact 4/10
Aug 17, 2026 SEC
Dermata Therapeutics entered into a securities purchase agreement for a ~$3.36M private placement, issuing shares…
8-K — Impact 7/10
Aug 16, 2026 Insider
PROEHL GERALD T was granted 170,068 shares
PRESIDENT, CHAIRMAN, CEO
Aug 16, 2026 Insider
PROEHL GERALD T was granted 170,068 shares
PRESIDENT, CHAIRMAN, CEO
Aug 16, 2026 Insider
PROEHL GERALD T was granted 1,360,544 shares
PRESIDENT, CHAIRMAN, CEO
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
20,203 shares ($26.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
DRMA Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 15, 2026
Trading halt
Halt Resumed: DRMA — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-15T14:26:49.000Z | Resumed 2026-10-15T14:31:49.000Z
Oct 15, 2026
Trading halt
Trading Halt: DRMA — LUDP (Volatility Trading Pause)
Dermata Therapeutics Cs | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 25, 2026
Reg SHO list
Reg SHO Threshold: DRMA exited the threshold list
DERMATA THERAPEUTICS INC COM P | On list since 2026-08-18
Aug 18, 2026
Reg SHO list
Reg SHO Threshold: DRMA entered the threshold list
DERMATA THERAPEUTICS INC COM P | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding
Aug 11, 2026
Earnings date
DRMA Q2 2026 Earnings Scheduled — 2026-08-11

SecBot reports

5 filings · 0 bullish · 2 bearish · 3 neutral
All DRMA filing & press-release reports (5)